

## **TITLE PAGE**

Title: Do physician outcome judgements and judgement biases contribute to inappropriate use of treatments? Study Protocol

Authors: Jamie C. Brehaut  
Ottawa Health Research Institute  
Ottawa Hospital, Civic Campus  
1053 Carling Avenue; ASB 2-004, Box 693  
Ottawa, Ontario K1Y 4E9  
Canada  
[jbrehaut@ohri.ca](mailto:jbrehaut@ohri.ca)

Roy Poses  
Foundation for Integrity and Responsibility in Medicine  
16 Cutler Street, Suite 104  
Warren, RI 02885  
USA  
[rposes@firmfound.org](mailto:rposes@firmfound.org)

Kaveh G. Shojania  
Ottawa Health Research Institute  
Ottawa Hospital, Civic Campus  
1053 Carling Avenue; C403, Box 683  
Ottawa, Ontario K1Y 4E9  
Canada  
[kshojania@ohri.ca](mailto:kshojania@ohri.ca)

Alison Lott  
Ottawa Health Research Institute  
Ottawa Hospital, Civic Campus  
1053 Carling Avenue; ASB 2-010, Box 693  
Ottawa, Ontario K1Y 4E9  
Canada  
[alott@ohri.ca](mailto:alott@ohri.ca)

\* Corresponding author

Malcolm Man-Son-Hing  
Ottawa Health Research Institute  
Ottawa Hospital, Civic Campus  
1053 Carling Avenue  
Ottawa, Ontario K1Y 4E9  
Canada  
[mhing@ohri.ca](mailto:mhing@ohri.ca)

Elise Bassin  
Oral Health Policy and Epidemiology  
Harvard School of Dental Medicine  
188 Longwood Avenue  
Boston, MA 02115  
USA  
[elise\\_bassin@post.harvard.edu](mailto:elise_bassin@post.harvard.edu)

Jeremy Grimshaw  
Ottawa Health Research Institute  
Ottawa Hospital, Civic Campus  
1053 Carling Avenue  
Ottawa, Ontario K1Y 4E9  
Canada  
[jgrimshaw@ohri.ca](mailto:jgrimshaw@ohri.ca)

## **ABSTRACT**

### **Background**

There are many examples of physicians using treatments inappropriately despite clear evidence about the circumstances under which the benefits of such treatments outweigh their harms. When such over- or under- use of treatments occur for common diseases, the burden to the healthcare system and risks to patients can be substantial. We propose that a major contributor to inappropriate treatment may be how clinicians judge the likelihood of important treatment outcomes, and how these judgements influence their treatment decisions. The current study will examine the role of judged outcome probabilities and other cognitive factors in the context of two clinical treatment decisions: 1) prescription of antibiotics for sore throat, where we hypothesize over-estimation of benefit and underestimation of harm leads to over-prescription of antibiotics; and 2) initiation of anticoagulation for patients with atrial fibrillation, where we hypothesize that under-estimation of benefit and over-estimation of harm leads to under-prescription of warfarin.

### **Methods/Design**

For each of the two conditions, we will administer surveys of two types (Type 1 and Type 2) to different samples of Canadian physicians. The primary goal of the Type 1 surveys is to assess physicians' perceived outcome probabilities (both good and bad outcomes) for the target treatment. Type 1 surveys will assess judged outcome probabilities in the context of a representative patient, and include questions about how physicians currently treat such cases, the recollection of rare or vivid outcomes, as well as practice and demographic details. The primary goal of the Type 2 surveys is to measure the specific factors that drive individual clinical judgements and treatment decisions, using a 'clinical judgement analysis' or 'lens modeling' approach. This survey will manipulate 8 clinical variables across a series of 16 realistic case vignettes. Based on the survey responses, we will be able to identify which variables have the greatest effect on physician judgements, and whether judgements are affected by inappropriate cues or incorrect weighting of appropriate cues. We will send antibiotics surveys to family physicians (300 per survey), and warfarin surveys to both family physicians and internal medicine specialists (300 per group per survey), for a total of 1800 physicians. Each Type 1 survey will be 2-4 pages in length and take about 15 minutes to complete, while each Type 2 survey will be 8-10 pages in length and take about 30 minutes to complete.

### **Discussion**

This work will provide insight into the extent to which clinicians' judgments about the likelihood of important treatment outcomes explain inappropriate treatment decisions. This work will also provide information necessary for the development of an individualized feedback tool designed to improve treatment decisions. The techniques developed here have the potential to be applied to a wide range of clinical areas where inappropriate utilization stems from biased judgements.

## **BACKGROUND**

The problem of inappropriate use of existing treatments represents a significant challenge for knowledge translation (KT) researchers. There is mounting evidence that a wide variety of treatments are either under- or over-used, and that this inappropriate use causes significant burden to health-care systems. For example, cardiovascular complications are the commonest cause of death among persons with diabetes, yet despite clear evidence of benefit, less than 25% of persons with diabetes receive statins, and less than 50% receive angiotensin-converting enzyme (ACE) inhibitors.<sup>1,2</sup> In contrast, other work has shown that benzodiazepines are over-used, despite clear guidelines that they should be used cautiously.<sup>3</sup> At a more general level, studies from the United States and the Netherlands suggest that ~30-40% of patients do not receive care according to current scientific evidence and ~20-25% of care provided is either not needed or potentially harmful.<sup>4-7</sup>

Knowledge Translation (KT) frameworks attempting to characterize the process of translating new evidence into practice change typically recognize the individual practitioner as a key component in the process. For example, the Ottawa Model of Research Use<sup>8</sup> describes three key elements that should be assessed for barriers and supports to research use: the practice environment, the research product itself, and the potential adopters of the research product. Another framework<sup>9</sup> describes four levels at which interventions to improve the quality of health-care might operate: the individual health professional; health-care groups or teams; organizations providing health-care; and the larger health-care system or environment in which individual organizations are embedded. To date, 80% of interventions used in evaluations of dissemination and implementation strategies targeting physicians have focused on the individual practitioner (e.g., continuing medical education, educational outreach, audit and feedback, reminders).<sup>10</sup> Despite all this research, the choices of what interventions to choose, and how to evaluate them, have been driven more by investigator preference than by explicit empirical or theoretical rationale. A rationale for intervention choice has not been developed, and the available knowledge about how individuals make decisions has not been considered. The current project will begin the work of applying existing cognitive psychological theory to the problem of changing physician behaviour at the level of the individual practitioner.

### **Theoretical basis for physician behaviour change: Human judgement and decision making**

Most KT frameworks recognize the individual practitioner as a key component in the process of practice change, because it is the practitioner who ultimately makes the diagnosis and treatment decisions. This is particularly true in areas where physician autonomy is high, as is the case with many kinds of pharmaceutical treatment. In these situations, it is ultimately the individual practitioner who decides whether or not to prescribe medicines for a given patient. In terms of understanding how individuals change their treatment behaviour, one area of psychological theory has been under-utilized. Cognitive psychology, and in particular the judgement and decision-making literature, has developed both theoretical frameworks and methods that could be

exploited to develop and improve KT interventions aimed at the individual practitioner.<sup>11-13</sup> The current work hinges on two fundamental claims that have their empirical foundation in the judgement and decision-making literature.

***Claim #1: Physicians' treatment decisions often depend on their judgements of treatment outcome probabilities.***

Judgement and decision making psychologists have proposed a variety of models of how people make decisions. These models range from “non-decision” behaviours, performed reflexively and without considering specific case features or alternative courses of action, to the hyper-rational (and unpragmatically complex) tenets of formal decision analysis.<sup>14</sup> Many psychologists now believe that human decision making often falls somewhere between these two extremes. Many decisions will incorporate common elements, such as identifying decision options and their possible outcomes, judging the likelihood and value of these outcomes, and then combining this information to make a decision.<sup>14</sup> Although errors can occur with any of these elements<sup>15</sup>, several lines of evidence lead us to study errors in judgements of outcome likelihood, and whether improving such judgements might increase appropriate use of treatments. First, there is considerable evidence showing that physicians have trouble accurately judging the probability of important clinical events and outcomes in a variety of clinical settings.<sup>16</sup> Second, several surveys have also suggested that physicians make decisions about pharmaceutical treatment according to their judgments of the likelihood of relevant outcomes.<sup>17</sup> Third, a pilot study by the authors showed that physicians use their judgements of treatment effectiveness and adverse reaction probabilities to decide upon treatment for congestive heart failure.<sup>16</sup> The two clinical problems selected for this current study involve pharmaceutical treatment decisions and share many characteristics with the pilot study condition. However, we will evaluate whether Claim #1 holds true for these two new clinical situations.

In short, changing physician treatment decisions may rest on improving physicians' judgements of outcome probabilities, particularly in areas (i.e. pharmaceutical treatment decisions) where there is physician autonomy. One of the goals of this project is to determine whether hypothetical treatment decisions involving two clinical conditions depend upon these judged outcome probabilities.

***Claim #2: Cognitive factors can cause errors in physician judgements of treatment outcome probabilities.***

There is clear evidence that physicians often make errors when making diagnostic or prognostic judgements<sup>18-22</sup>, and that individual physicians<sup>23</sup> and groups of physicians<sup>24</sup> vary in their ability to make these judgements. Many of these errors have been attributed to “cognitive biases”, which can be defined as the tendency to systematically over- or underestimate particular outcome probabilities. An example of such a tendency is “ego bias”, which is the tendency to believe that one's own performance is likely to be better than average.<sup>25</sup> One study showed that ego bias can lead to systematic errors in physicians' prognostic judgments for critically ill patients.<sup>5</sup>

In addition to studying systemic errors or biases in the thinking of decision makers, considerable work has focused on cognitive ‘heuristics’. These simple mental rules-of-thumb very often produce accurate judgements and are thus highly efficient.<sup>26;27</sup> However, in some situations such shortcuts actually mislead and degrade some diagnostic and prognostic judgments. For example, the “availability heuristic” bases the judgment of a particular outcome probability on the ease with which one can recall instances of similar outcomes.<sup>24</sup> Since vivid events are often more easily recalled than mundane ones, this heuristic could cause one to over-estimate the likelihood of unusual or bizarre cases and underestimate the likelihood of more commonplace ones. For example, previous studies have shown that the availability heuristic may affect physicians' diagnostic judgments for bacteremia.<sup>24</sup> One of the goals of the current work is to determine the extent to which cognitive heuristics such as availability contribute to the inappropriate use of treatments by physicians.

Some cognitive factors might be expected to affect disproportionately certain subsets of physicians. For example, one study found that the “illusion of control”, the tendency to have too much faith in one’s own ability to control future events<sup>28;29</sup>, can explain why cardiologists generally judge the outcomes of adverse events due to cardiac procedures to be less likely than do other internists.<sup>30</sup> Furthermore, those less experienced in making these decisions, or those who see such cases less often, may be more likely to have their decisions affected by indicators not reliably associated with the outcome, but that nevertheless have some face validity in terms of the outcome. For example, a cracking sound at the time of an ankle injury is unrelated to the presence of a fracture, yet many less experienced emergency physicians report considering this indicator when deciding whether to order radiography.<sup>31;32</sup> Examination of the extent to which groups of decision makers differ in their assessments of outcome probabilities and their relative susceptibility to different cognitive biases warrants further study.

### **Examples of clinical therapies that are inappropriately utilized**

The aim of this project is to understand whether inappropriate treatment decisions might be associated with judged outcome probabilities and other cognitive factors. Two clinical conditions were selected; one in which treatment is generally over-utilized, the other where it is under-utilized. We examine both over- and under-utilization because changing an existing, well-practiced behaviour (i.e. reducing the use of over-utilized treatments) may require different change mechanisms than beginning a new behaviour (i.e. adopting an under-utilized treatment). This proposal focuses on two specific treatments: the over-prescription of antibiotics for pharyngitis treatment, and the under-use of warfarin (Coumadin) for treatment of chronic atrial fibrillation (AF).

Our goal for both clinical conditions is to understand relationships between treatment decisions and judged probabilities of ‘outcomes’; i.e. the benefits and harms that might stem from a given treatment. These benefits and harms differ depending on the clinical condition. In the case of antibiotics for pharyngitis, relevant outcomes will include resolution of symptoms, local and systemic complications from such infections (e.g., peritonsillar abscess and glomerulonephritis), and complications of treatment, such as

adverse drug reactions (ADRs). In the case of warfarin treatment for AF, key outcomes will include stroke (fatal or permanently disabling) and major hemorrhages (fatal, intracranial, or other bleeds requiring hospitalization). For the current purposes, the umbrella term ‘outcomes’ will be used to refer to all potential treatment benefits and harms.

### **Under-use of warfarin (Coumadin) for treatment of atrial fibrillation**

There are many documented examples of physicians failing to use treatments where the benefits clearly outweigh the risks and costs. Such failures to use effective treatments<sup>33-43</sup> can have major implications on health-related costs and overall patient care<sup>7</sup>, and guideline developers argue that the detection of instances when physicians fail to use treatments of proven effectiveness should be a cornerstone of quality assessment.<sup>44</sup> One example of an effective treatment that is under-used is anti-coagulation with warfarin (Coumadin) for the treatment of chronic atrial fibrillation (AF). AF is a common cardiac arrhythmia, affecting 5% of the population over the age of 65.<sup>45;46</sup> While AF increases the risk of stroke six-fold<sup>47;48</sup>, use of the anti-coagulant warfarin can substantially reduce that risk.<sup>49</sup> However, there is evidence that despite its effectiveness, anti-coagulants are only taken by 30-60% of appropriate patients. A variety of reasons for this under-use, including those to do with its perceived outcome probabilities by prescribing physicians<sup>50-52</sup>, have been proposed but never empirically tested. We will survey samples of family physicians and internal medicine specialists about their practice of prescribing anti-coagulation for people with AF.

### **Over-use of antibiotics for sore throat (pharyngitis)**

Bacterial resistance to antibiotics has become a global public health problem.<sup>53;54</sup> The over-use of antibiotics by humans is clearly an important cause of this problem<sup>53</sup>, much of which can be attributed to the prescribing practices of physicians.<sup>54</sup> One study<sup>55</sup> found that physicians prescribed antibiotics for between 57% and 74% of patients with pharyngitis. Yet despite the widespread use of antibiotics for pharyngitis, the literature shows very little evidence of the effectiveness of these treatments in terms of speed of symptom resolution, or lower rates of adverse events among patients with pharyngitis. While some evidence may demonstrate effectiveness of narrow-spectrum antibiotics among patients with high likelihood of streptococcal pharyngitis<sup>56-58</sup>, these benefits do not appear to extend to the wider population of all patients with pharyngitis. Furthermore, the use of broad spectrum antibiotics for pharyngitis may be on the rise, yet there is no evidence of any increased benefit of these antibiotics over more narrow-spectrum choices.<sup>55;59;60</sup>

Our review identified four studies that compared cephalosporins to penicillin, all of which showed no benefits.<sup>61-64</sup> Five studies showed no evidence that extended-spectrum macrolides produce any improvement over penicillin V or erythromycin.<sup>65-70</sup> The one study comparing amoxicillin/clavulanic acid to penicillin also failed to show any benefits of the antibiotic.<sup>71</sup> No studies have compared the use of any fluoroquinolone or broad-spectrum antibiotic to penicillin among patients with pharyngitis. In short, the literature

on treatment for pharyngitis does not justify use of antibiotics on the general population of patients with pharyngitis, and has failed to uncover any evidence that broad-spectrum antibiotics produce any additional benefit over narrow-spectrum choices like penicillin. Previous interventions to reduce antibiotic use have met with limited success. Some methods involving personalized feedback have been somewhat effective, although these interventions are also labor-intensive, costly and complex, with little known about the extent to which the observed practice change is sustained.<sup>72;73</sup>

## **Hypotheses**

The goal of the current work is to examine the role of judged outcome probabilities and other cognitive factors in the context of two treatment decisions: use of antibiotics for patients with pharyngitis, and use of anti-coagulants for treatment of AF. We will examine whether physician-specific outcome judgements contribute to inappropriate treatment decisions in these two clinical contexts. The study will address five specific hypotheses:

- 1) Physicians' decisions to use specific treatments depend on their judgements of the likelihood of treatment outcomes;
- 2) Physician judgements of the likelihood of treatment outcomes will sometimes be inaccurate;
- 3) Specific judgement heuristics can account for some of the inaccuracies of physician judgements of treatment outcomes;
- 4) Predictable groups of physicians will be more apt to be inaccurate in their judgements of treatment outcomes;
- 5) Judgement inaccuracies will stem from physicians attending to cues that are unrelated to treatment outcomes, and/or insufficiently attending to cues that are related to outcomes.

## **DESIGN / METHODS**

This project will consist of a series of four mailed surveys to Canadian physicians, two focused on the use of antibiotics for pharyngitis, and two on the use of anti-coagulants for treatment of AF. For each clinical condition, one survey (Type 1) will measure the accuracy of judged probabilities of treatment-related outcomes, while the other (Type 2) will use a series of realistic case vignettes to determine what factors affect treatment decisions.

Development of the various surveys will require us to perform the following tasks: systematically review the relevant clinical literatures to identify the characteristics of patients to whom the research results would generalize; identify the important outcomes, good and bad, conditional on treatment; develop evidence-based estimates of the population rates of these outcomes conditional on choice of treatment; and assess the evidence about patient factors that may predict these outcomes. We will also review the available evidence about factors that influence physicians' decisions around use of the treatment. We will construct and pilot test surveys to evaluate physicians' judgments and

decisions based on this work. These surveys will be informed by pilot work done in the United States on a different range of clinical subspecialties.

## **Procedure**

Two survey types will be employed for each clinical condition. The primary goals of the Type 1 surveys will be to assess physicians' perceived outcome probabilities (good and bad) for different treatments, and to compare these perceived probabilities to the real rates indicated by the systematic reviews (Hypothesis 2). These goals will be achieved by having physicians assess a hypothetical patient representative of those included in the most important and relevant RCTs of the target condition. The survey will assess judged outcome probabilities, by asking physicians to quantify the likelihood of various outcomes if 100 patients similar to this hypothetical patient were to be treated. The Type 1 surveys will also ask physicians about how they currently treat such cases, the recollection of rare or vivid outcomes (Hypothesis 3), as well as practice and demographic details.

The primary goals of the Type 2 surveys will be to measure specific factors that drive individual clinician judgements and treatment decisions (Hypothesis 5), and to determine whether individual physician judgements predict treatment decisions (Hypothesis 1). These goals will be achieved by having physicians consider 16 realistic case vignettes about hypothetical patients with the target condition. Eight clinical variables will be varied systematically across the 16 case vignettes using a partial factorial design. For example, the manipulated variables in the antibiotics vignettes could include factors related to clinical outcomes (e.g. Centor criteria predicting strep: cough, fever, tonsillar exudates, tender lymph nodes), as well as non-predictive variables that might be perceived as predictive (e.g. age, sex, occupation). The vignettes will prompt physicians to indicate what management decision they would select for each clinical variable combination. These responses will allow for the identification of which variables have the greatest effect on physician judgements, and whether such judgements are affected by non-predictive cues or the unrealistic expectations of appropriate cues.

We will mail each of the four surveys to different random samples of Canadian physicians. The physician population will be determined by the clinical condition. The pharyngitis surveys will be administered to different samples of 300 family physicians. Each warfarin survey will be administered to 300 family physicians and 300 internal medicine specialists; this design reflects the fact that this clinical decision is made by both groups of physicians. It will also allow us to examine differences in decision making between the two different disciplines (Hypothesis 4).

We therefore propose to mail four different surveys to a total of 1800 physicians (1200 family physicians and 600 internal medicine specialists). The names, addresses, and telephone numbers of these physicians will be obtained from the Canadian Medical Association Directory and membership lists of specialty organizations, such as the Canadian College of Family Physicians and the Royal College of Physicians and Surgeons of Canada. The sampling population will be limited to English-speaking

physicians, since the detailed nature of the surveys would make translation into French extremely time-consuming, requiring a lengthy series of iterations of translation and back-translation to ensure comparability between languages. Random selection from membership lists will result in a sampling population that has approximately the same ratio of physicians from all provinces and territories as in the membership list.

The four surveys will be administered through the Ottawa Health Research Institute. While considerable research has demonstrated the difficulty of obtaining high response rates from physicians, the members of this team have considerable experience in doing so with comparable populations.<sup>16;31;74-76</sup> This project will employ the Dillman Tailored Design Method for survey design and implementation<sup>77</sup>, which is one of the most widely used and tested surveying methods. Although this design was originally designed for general public surveys, a recent systematic review demonstrated that the recommendations of the Dillman method also apply to surveys of physicians.<sup>78</sup> In accordance with the design, an initial pre-notification letter will be sent to all selected physicians and the survey will follow one week later. A series of three reminders and two replacement surveys will then be mailed out to non-responders at 2 week intervals. All correspondences will be addressed to the individual physicians, and personally signed by the principal investigator.

The characteristics of the responders and non-responders for each of the four surveys will be compared, to determine how the generalizability of the survey results may be affected by response bias. This physician-specific information will be obtained from the membership lists used to derive the sampling population. The Dillman method has previously been employed to survey Canadian physician society lists, yielding response rates in excess of 80%.<sup>79;80</sup> The Type 1 surveys will be 2-4 pages in length and take approximately 15 minutes to complete. In contrast, the Type 2 surveys will be 8-10 pages in length and take about 30 minutes to complete. There is extensive literature showing that non-trivial financial incentives can improve physician survey response rates anywhere from 8.6% to 48.5%.<sup>78</sup> As a result, a \$20 incentive will be offered to all survey participants who return a completed survey.

### **Data quality and Data collection**

Quality assurance procedures will be implemented to ensure the integrity of the survey data collection.<sup>81;82</sup> All aspects of the protocol will be elaborated in a detailed protocol manual for the study team. For the surveys, a log record will be initiated and maintained to track the study status of participants throughout the mailings of the surveys. To ensure confidentiality, participants will be assigned a code number for use on all subsequent study documentation.

The survey data will be entered into a SAS database by the Data Management Group of the Clinical Epidemiology Program at the Ottawa Health Research Institute. Upper and lower limits will be set for each variable, allowing the database program to detect immediately and highlight logical and range errors requiring correction. In order to assess data entry accuracy, ten percent of case records will be randomly selected and re-entered.

If this data check finds an error rate greater than 1%, the accuracy of the data will be considered unacceptable and all cases will be re-entered then re-assessed.

## **Analysis**

### ***Hypothesis 1: Physicians' decisions to use specific treatments depend on their judgements of the likelihood of treatment outcomes***

This hypothesis will be evaluated using data from the Type 2 surveys. After adjusting for covariates, data will be examined to determine the extent to which individual judged outcome likelihoods predict treatment decisions across the 16 cases. For example, physicians completing the Type 2 antibiotics survey will be asked to judge the proportion of patients for whom sore throat pain would resolve by Day 3 if they 1) were given no antibiotic, or 2) were given penicillin. By subtracting the second value from the first, we can determine the judged absolute increase in likelihood of symptom resolution due to use of the antibiotic. We will then determine the extent to which differences in these outcome likelihood judgements across cases predict differences in treatment decisions (after controlling for additional factors such as demographic characteristics, specialty, practice setting, etc). The analytic strategy for this hypothesis will rely on the use of hierarchical or mixed model regression, which permits the estimation of physician-specific coefficients and the inclusion of physician-level covariates.<sup>83-85</sup> For example, the analysis of the decision to treat with antibiotics could be performed using a hierarchical multivariate regression models for an individual physician, 'physician I'. This model will take the form  $TR_{ij}=b_{0i} + b_{1i} A_{ij} + b_{2i} B_{ij} + b_{3i} C_{ij} + \text{error}$ , where  $TR_{ij}$  represents how strongly physician  $i$  feels about the patient's treatment in vignette  $j$ ;  $b_{0i}$  is a physician specific intercept; and  $A_{ij}$  and  $B_{ij}$  represent within- physician covariates.

The second level of the model will describe variation between physicians. This level will ordinarily assume that the coordinates ( $b_0$ ,  $b_1$ ,  $b_2$ , etc.) vary at random across physicians. These coordinates measure the effect of the components of A, B, and C within physician  $i$ . The authors will also consider using models where the intercept and the coefficients of A, B, and C are functions of physician characteristics.

The hierarchical model will provide estimates of the physician-specific coefficients and components of variance. The more elaborate models will also provide estimates of coefficients describing between-physician variability as a function of physician characteristics (components of specialty, practice setting, etc). The model fitting process will use standard software for hierarchical and mixed models, including subroutines from SAS, MLWin<sup>85</sup> and BUGS.<sup>86</sup>

### ***Hypothesis 2: Physician judgements of the likelihood of treatment outcomes will sometimes be inaccurate***

To evaluate this hypothesis, data from the Type 1 surveys will be used to test whether judged outcome likelihoods for a representative patient match best evidence from systematic reviews. For example, judged absolute increase in resolution of symptoms due

to antibiotics use will be computed as described above (Hypothesis 1). The scenario in this survey will be based on a prototypical patient eligible for the large RCTs that provide the best estimates of the true values. This will allow the comparison of judged estimates with the 95% confidence intervals reported by these trials and tabulation of the percentage of physicians that are outside the 95% confidence intervals (maintaining beliefs that have been “ruled out” by the trials). We will graphically display the distribution of the physicians’ judgments compared to the trials’ best estimate and surrounding 95% confidence intervals.

***Hypothesis 3: Specific judgement heuristics can account for some of the inaccuracies of physician judgements of treatment outcomes***

Type 1 surveys will include questions on whether rare or vivid outcomes had been seen by the physician in the previous year. The extent to which the answers to this question affect judgement accuracy will be analyzed using an approach similar to that for Hypothesis 1. Note, however, that there will only be one observation per physician, therefore hierarchical modeling will not be required. This analysis will test whether experience of and memory for rare, bizarre, or vivid outcomes (e.g. suppurative complication of a streptococcal infection) affect the assessment of the overall likelihood of such an outcome. The response variable in the regression models will be the assessment of the likelihood of outcome for the case presented in the Type 1 survey. Independent variables will include physician characteristics (e.g. demographics, specialty, and practice setting) and the physicians’ recollections of rare outcomes.

***Hypothesis 4: Predictable groups of physicians will be more apt to be inaccurate in their judgements of treatment outcomes***

This hypothesis will be addressed using data from the Type 1 warfarin survey. The judged likelihood of outcomes for each physician will be calculated then compared with the best evidence, as indicated for Hypothesis 2. After controlling for a variety of covariates (age, gender, practice setting, etc.), the accuracy between the physicians' specialty groups will be compared (family physicians and internal medicine specialists). If groups differ in accuracy after controlling for the covariates, exploratory analysis will examine which decision cues could explain these differences, and whether differential reliance on these decision cues between groups explain the group differences in accuracy. These decision cues will then be further examined and purposely varied in the Type 2 survey. For example, logistical concerns about managing warfarin therapy may be more relevant to family physicians than internists (who often are not responsible for long-term management), and might therefore contribute to group differences. Systematic manipulation of this cue in the Type 2 survey would reveal whether this cue contributes to group differences in treatment decisions.

***Hypothesis 5: Some judgement inaccuracies will stem from physicians attending to cues that are unrelated to treatment outcomes, and or underweighting cues that are related to outcomes***

This hypothesis will be evaluated using data from the Type 2 surveys. The analytical approach is identical to that described in Hypothesis 1, with the response variable being “judged probability” instead of treatment decision. This approach is conceptually inspired by lens modeling, otherwise known as social judgement analysis.<sup>87-89</sup> The approach involves systematically varying the levels of several sources of information (cues) between a series of vignettes. From these vignettes, the judgement strategies employed by physicians when making their diagnoses can be inferred. This judgement strategy can be represented as a linear regression model, with standardized regression weights describing the relative importance of each cue in determining a physician’s diagnosis. While the linear model does not necessarily indicate what the physician was thinking at the time of judgement, it will predict those judgements accurately<sup>90</sup>, and indicate which cues affected judgement.<sup>91</sup>

We will also tabulate the proportion of physicians for whom one or more of the non-predictive variables have coefficients different from zero, as assessed by the 95% posterior probability region; this implies these variables are used as predictors of either benefits or harms. We will then tabulate the proportion of physicians using each specific type of variable to make their judgments.

For all regression models, we will employ graphical approaches to look for outliers and influential observations, while statistics measuring model fit will also be calculated. Steps to control the extent of missing data items will be built into each aspect of the data collection and data management process. During the final analysis of the data we will rely on multiple imputation techniques to handle the presence of missing data elements. We will also compare the results to those obtained from the analysis based on complete cases only.

### **Sample size and Power**

Our survey response rate estimates are based on previous similar work examining the physicians’ treatment decisions for patients with HIV.<sup>76</sup> That study involved mailing a Type 1 survey to a random sample of 2495 physicians from the American Medical Association master file. Similar methods to those planned for the current proposal were also used to enhance participation, including an honorarium of \$10 per physician. Of all surveys distributed, 3.8% (96/2495) were returned due to an incorrect address, and 2.6% (65/2495) were returned because the physician had retired. The final response rate for the eligible physicians in this study was 51.4%. Given our plan to mail each survey to a minimum of 300 physicians, we expect 6% will be ineligible, leaving 282 eligible. Of these, we expect at least 50% will return completed surveys. Thus our expected minimum total sample size will be 141 for each survey. In the case of the warfarin surveys we expect 141 family practitioners, and 141 internal medicine specialists to respond.

Hypothesis 4 will involve measuring the difference in accuracy between two groups. Assuming a minimum critically important difference in accuracy of 0.5 standard deviations, the power with a type one error rate of 5% and 141 physicians per group will

be 0.98%. As we will likely need to adjust for some covariates in this comparison of accuracy, some allowance needs to be anticipated. Previous simulation studies have suggested that over 90% power is maintained, giving an overall power of 0.882%.<sup>92</sup>

Hypotheses 1, 3, & 5 involve prediction both within and across physicians, but it is only in the latter case where power becomes an issue, as statistical significance of factors within a particular physician is not an important issue in this study. Drawing on sample size conventions for prediction<sup>93</sup> and taking physician as the observation, we have chosen to estimate the number of physicians needed on the basis of the number of degrees of freedom (df) in the covariates that need to be modelled. We propose to include gender (1 df), years of experience (2 df), practice setting (2 df), volume of relevant cases (1 df), current test ordering practice (1 df), and previous experience with rare side effects (1 df). A total of 8 df multiplied by a rule of thumb 15 observations per degree of freedom<sup>93</sup> suggests we need at approximately 120 respondents; we expect 141. Hypothesis 2 involves determining the percent of physicians that maintain judged outcome likelihoods that have been ruled out by 95% conf intervals from trials. The 95% percent confidence interval for the percent of physicians based on assuming maximum variance ( $p=.5$ ) will be less than  $+ \text{ or } - 1.96 * \text{sqrt} (.25/141) = 0.082$ .

## **DISCUSSION**

We see this work as a necessary pre-requisite for the development and implementation of an intervention that will increase the accuracy of judged outcome probabilities and thus improve treatment utilization. In the next phase of this work, we will use findings from this study to develop a computerized feedback task designed to improve the accuracy of these judgements. This study will tell us the scope of the inaccuracies for our two clinical decisions, determine a number of sources of these inaccuracies, establish which physicians make which sorts of error, and allow us to determine what kinds of feedback will be most effective in improving judgement accuracy.

This work will be the first to assess in detail possible reasons for physicians' suboptimal management of two very important medical situations: the use of antibiotics for sore throat, and the use of anti-coagulants for treatment of AF. It will be the first large-scale study to examine the relationship between physician-specific judgement characteristics and medical decisions for important, inappropriately treated clinical conditions. It will also be the first to examine the accuracy of outcome judgements for these clinical conditions, and to examine whether they are affected by judgement heuristics and biases.

We believe that the current proposal will have far-reaching implications. It will provide insight as to why physicians persistently use treatments inappropriately, despite clear evidence about how they should be used. More importantly, this work will lead directly to the development of focused interventions that could greatly improve treatment utilization. For instance, the development of online computer software that provides physicians with direct, immediate feedback comparing their outcome probability estimates to the best available evidence may lead to substantial improvements in judged

outcome probabilities. While the question of whether such improvements lead to improved treatment behaviour must be left to a future full-scale RCT, the ground work proposed here will allow us to determine whether developing such a tool to be the focus of an RCT would be warranted.

It is likely that a wide variety of other treatment situations are also affected by inappropriate outcome estimates. If this study turns out as we expect, it will suggest that studying other important instances of inappropriate use with similar methods may be warranted. For example, it is quite common to see over-utilization of expensive, invasive, and/or high technology interventions, such as percutaneous transluminal coronary angioplasty (PTCA)<sup>94</sup>, and screening for prostate cancer with prostate specific antigen (PSA) assays<sup>95;96</sup>, without convincing evidence of the effectiveness of these interventions. The techniques proposed here will provide a mechanism to understand the judgement processes that go into the use of these interventions, and potentially to increase appropriate use.

## **Limitations**

Some of the potential limitations of the proposed work are common to any work that involves survey-based data collection. First, the extent to which the responses provided by physicians to these survey-based vignettes reflect real-world management of patients in actual practice is unclear. However, evidence is accumulating to support the validity of clinical case-vignette based research. Physician decisions in response to case-vignettes generally mirror their decision making for simulated patients with the same clinical problem. Furthermore, the vignette approach approximates real-world decision making much better than does data from standard chart abstraction techniques.<sup>97-99</sup> We have carefully tried to maximize the validity of our vignettes by 1) using vignettes with high face validity; 2) allowing for responses similar to those one might make in practice; 3) avoiding "cueing" subjects by listing responses they are unlikely to consider in real life; and 4) avoiding suggesting which responses are expected.<sup>99</sup> We will further pilot test draft surveys to ensure that the vignettes are as representative of real-world decisions for our specific physician audiences as possible.

There is some possibility of significant response bias, given that we have conservatively projected our response rate to be 50%. This level of responding is consistent with our experience with this type of survey<sup>76</sup>, as well as other similar surveys<sup>100-102</sup>, while recent systematic reviews have estimated similar overall mean response rates to physician surveys.<sup>103;104</sup> There is evidence that physicians who do not respond to mailed surveys are less active in and knowledgeable about the relevant clinical areas than those who do respond.<sup>105</sup> This might mean that our results will understate the difficulties physicians have judging outcomes of the treatment of interest, and the degree they use non-predictive variables to make these judgments. However, any such response bias would result in greater (not reduced) accuracy in judgements, and thus if anything reduce the likelihood of supporting Hypothesis 2, by yielding a conservative estimate of the extent to which these physicians make inaccurate outcome judgements.

Finally, it may be that some treatment decisions depend as much on the value or importance placed on the outcomes as they do on their likelihood. Evidence suggests this may be true of patient decision-making, where the presence of vivid but rare potential side effects can have disproportionate effects on decision making<sup>106</sup>, and may well be true of physician decision making as well. For example, we have observed that treatment differences between UK and US physicians deciding about drug therapy for seizure patients may stem from differences in the judged importance of particular side-effects. Indeed, some have argued that for physicians "value is a consideration in every decision representation."<sup>14</sup> While methods of measuring the values or importance of health outcomes (called "utilities" in decision analysis) exist, these methods are complex and time-consuming; we therefore decided to limit the scope of the current project to a consideration of judged outcome likelihood.

### **Changes to the Protocol after funding**

This protocol has been peer-reviewed and approved for funding by the Canadian Institutes of Health Research, and has ethics approval from the Ottawa Hospital Research Ethics Board. Our original proposal targeted two clinical conditions: use of antibiotics for sore throat, and the use of HMG Co-A reductase inhibitors (statins) for coronary artery disease (CAD) and hypercholesterolemia. When detailed planning began after funding was received, the literature on use of statins for CAD had grown more complex, such that it was less clear whether statins are universally under-used, or may instead be under-used in some populations and over-used in others. Because of the increasing complexity of this literature, and because our methodology would have required focusing on a relatively specific patient population group (making it more difficult to find physician respondents that deal with the specific group), we decided to not pursue statin use in our study, and instead to focus on anti-coagulants for atrial fibrillation. Techniques as discussed in this proposal have not changed from the original proposal.

## **LIST OF ABBREVIATIONS USED**

ACEI	ACE inhibitor
ADR	Adverse drug reactions
AF	Atrial fibrillation
CAD	Coronary artery disease
CHF	Congestive heart failure
CIHR	Canadian Institute of Health Research
CRTN	Canadian Research Transfer Network
Df	Degrees of freedom
HIV	Human immunodeficiency virus
KT	Knowledge translation
MI	Myocardial infarction
PSA	Prostate specific antigen
PTCA	Percutaneous transluminal coronary angioplasty
RCT	Randomized control trial
REB	Research ethics board

## **COMPETING INTERESTS**

None.

## **AUTHOR'S CONTRIBUTIONS**

RP conceived the general research questions. JB and RP wrote the proposal. RP, MH, KS, EB, and JG provided specific clinical and/or methodological expertise. AL and JB wrote the protocol and methodology. All authors contributed to the development of the specific research questions and reviewed the proposal and protocol.

## REFERENCES

1. Marchioli R, Marfisi M, Carinci F, Tognoni G. Meta-analysis, clinical trials, and transferability of research results into practice: the case of cholesterol-lowering interventions in the secondary prevention of coronary heart disease. *Arch Intern Med* 1996; **156**: 1158-72.
2. Brown LC, Johnson JA, Majumdar SR, Tsuyuki RT, McAlister FA. Evidence of suboptimal management of cardiovascular risk in patients with type 2 diabetes mellitus and symptomatic atherosclerosis. *Canadian Medical Association Journal* 2004; **171**(10): 1189-92.
3. Pimlott NJ, Hux JE, Wilson LM, Kahan M, Li C, Rosser WW. Educating physicians to reduce benzodiazepine use by elderly patients: a randomized controlled trial. *CMAJ* 2003; **168**(7): 835-9.
4. Schuster M, McGlynn E, Brook RH. How good is the quality of health care in the United States? *Milbank Quarterly* 1998; **76**: 517-63.
5. Poses RM, McClish DK, Bekes C, Scott WE, Morely JN. Ego bias, reverse ego bias, and physicians' prognostic judgements for critically ill patients. *Crit Care Med* 1991; **19**: 1533-9.
6. Chassin MR, Galvin RW. The urgent need to improve health care quality. Institute of Medicine National Roundtable on Health Care Quality. *JAMA* 1998; **280**(11): 1000-5.
7. McGlynn EA, Asch SM, Adams J, Keesey J, Hicks J, DeCristofaro A, Kerr EA. The quality of health care delivered to adults in the United States. *N Engl J Med* 2003; **348**(26): 2635-45.
8. Logan J, Graham ID. Toward a comprehensive interdisciplinary model of health care research use. *Science Communication* 1998; **20**: 227-46.
9. Ferlie E, Shortell S. Improving the quality of health care in the United Kingdom and the United States: a framework for change. *The Milbank Quarterly* 2001; **79**: 281-315.
10. Grimshaw JM, Thomas R, MacLennan G. Effectiveness and efficiency of guideline dissemination and implementation strategies. *Cochrane Database Syst Rev* 2002; **3**.
11. Elstein AS, Schwartz A. Clinical problem solving and diagnostic decision making: selective review of the cognitive literature. *BMJ* 2002; **324**: 729-32.
12. Patel VL, Glaser R, Arocha J. Cognition and expertise: acquisition of medical competence. *Clinical Investigations in Medicine* 2000; **23**: 256-60.

13. Patel VL, Kaufman D, Arocha J. Emerging paradigms of cognition in medical decision-making. *Journal of Biomedical Informatics* 2002; **35**: 52-75.
14. Yates JF. *Judgement and Decision Making*. Englewood Cliffs, NJ: Prentice-Hall, 1990.
15. Poses RM. One size does not fit all: questions about changing physician behavior. *Joint Comm J Qual Improve* 1999; **25**: 486-95.
16. Poses RM, Woloshynowych M, Chaput de Saintonge DM. Physicians' judgments of outcomes of treatment for heart failure. *Med Decis Making* 1998; **18**: 486.
17. Bradley CP. Decision making and prescribing patterns - a literature review. *Fam Pract* 1991; **8**: 276-87.
18. Dawes RM, Faust D, Mechi PE. Clinical versus actuarial judgment. *Science* 1989; **243**: 1668-74.
19. Berlowitz DR, Ghalill K, Moskowitz MA. The use of follow-up chest roentgerograms among hospitalized patients. *Arch Intern Med* 1989; **149**: 821-5.
20. Samet JH, Shevitz A, Fowle J, Singer DE. Hospitalization decision in febrile intravenous drug users. *Am J Med* 1990; **89**: 53-7.
21. Shulman KA, Escarce JE, Eisenberg JM, Hershey JC, Young MJ. Assessing physicians' estimates of the probability of coronary artery disease: the influence of patient characteristics. *Med Decis Making* 1992; **12**: 109-14.
22. Poses RM, Cebul RD, Collins M, Fager SS. The accuracy of experienced physicians' probability estimates for patients with sore throats. *JAMA* 1985; **254**: 925-9.
23. Poses RM, Bekes C, Copare F, Scott WE. The answer to "what are my chances, doctor?" depends on whom is asked: prognostic disagreement and inaccuracy for critically ill patients. *Crit Care Med* 1989; **17**: 827-33.
24. Poses RM, Anthony M. Availability, wishful thinking, and physicians' diagnostic judgments for patients with suspected bacteremia. *Med Decis Making* 1991; **11**: 159-68.
25. Weinstein N. Optimistic biases about personal risks. *Science* 1989; **246**: 1232-3.
26. Tversky A, Kahneman D. Judgement under uncertainty: Heuristics and biases. *Science* 1974; **185**: 1124-31.
27. Gigerenzer G, Todd PM, ABC Research Group. *Simple Heuristics That Make Us Smart*. Oxford: Oxford University Press, 1999.

28. Langer EJ. The illusion of control. *J Pers Soc Psychol* 1975; **32**: 311.
29. Weinstein ND. Unrealistic optimism about future life events. *J Pers Social Psychol* 1980; **39**: 806-20.
30. Poses RM, McClish DK, Smith WR, Chaput de Saintonge DM. Physicians' judgments of the risks of cardiac procedures: differences between cardiologists and other internists. *Med Care* 1997; **35**: 603-17.
31. Brehaut JC, Stiell I, Graham I, and Visentin L. Clinical decision rules 'in real world': How a widely disseminated rule is used in everyday practice. *Academic Emergency Medicine* 2005; **12**(10): 948-956.
32. Stiell IG, Wells GA, Hoag RH, Sivilotti ML, Cacciotti TF, Verbeek PR *et al*. Implementation of the Ottawa Knee Rule for the use of radiography in acute knee injuries. *Journal of American Medical Association* 1997; **278**: 2075-9.
33. Khan AH. Beta-adrenoreceptor blocking agents: their role in reducing chances of recurrent infarction and death. *Arch Intern Med* 1983; **143**: 1759-62.
34. Olson G, Wikstrand J, Warnold J, McBoyle D, Herlitz J. Metoprolol-induced reduction in post infarction mortality; pooled results from five. Double-blind randomized trials. *Eur Heart J* 1992; **13**: 28-72.
35. Yusuf S, Wittes J, Friedman L. Overview of results of randomized clinical trials in heart diseases: I. treatments following myocardial infarction. *JAMA* 1988; **260**: 2088-93.
36. Lau J, Antman EM, Jiminez-Silva J, Kipelnick B, Mosteller F, Chalmers RC. Cumulative meta-analysis of therapeutic trials for myocardial infarction. *N Engl J Med* 1992; **327**: 248-54.
37. Gorwitz JH, Goldberg RJ, Chen Z, Gore JM, Alpert JS. Beta-blocker therapy in acute myocardial infarction: evidence for under-utilization in the elderly. *Am J Med* 1992; **93**: 605-10.
38. Karlson BW, Herlitz J, Hjalmarson A. Impact of clinical trials on the use of beta-blockers after acute myocardial infarction and its relation to other risk indicators for death and 1-year mortality rate. *Clin Cardiol* 1994; **17**: 311-6.
39. Pagley PR, Chen Z, Yarzebski J, Goldberg R, Chiriboga D, Dalen P. Gender differences in the treatment of patients with acute myocardial infarction: a multi-hospital, community based perspective. *Arch Intern Med* 1993; **153**: 625-9.
40. Sial SH, Malone M, Freeman JL, Battiola R, Nachodsky J, Goodwin JS. Beta-blocker use in the treatment of community hospital patients discharged after myocardial infarction. *J Gen Intern Med* 1994; **9**: 599-605.

41. Thompson PL, Parsons RW, Jamrezik K, Hockey R, Hobbs MST, Broadhurst RJ. Changing patterns of medical treatment in acute myocardial infarction: observations from the Perth MONICA project 1984-1990. *Med J Austr* 1992; **157**: 87-92.
42. Tsuyoki RT, Teo KK, Ikuta RM, Bay KS, Greenwood PV, Montague TJ. Mortality risk and patterns of practice in 2070 patients with acute myocardial infarction, 1987-92: relative importance of age, sex, and medical therapy. *Chest*. 1994; **105**: 1687-92.
43. Van De Werf F, Topol EJ, Lee KL, Woodlief LH, Ganger CB. Variations in patient management and outcomes for acute myocardial infarction in the United States and other countries: results from the GUSTO trial. *JAMA* 1995; **273**: 1586-91.
44. Evidence-Based Resource Group. Evidence-based care: 1. Setting priorities: how important is the problem? 2. Setting guidelines: how should we manage the problem? Measuring performances: how are we managing the problem? *Can Med Assoc J* 1994; **150**: 1249-579.
45. Feinberg WM, Blackshear JL, Laupacis A, Kronmal R, Hart RG. Prevalence, age distribution, and gender of patients with atrial fibrillation. *Arch Intern Med* 1995; **155**: 469-73.
46. Man-Son-Hing M, Laupacis A. Anticoagulant-Related Bleeding in Older Persons with Atrial Fibrillation. *Arch Intern Med* 2003; **163**: 1580-6.
47. Buckingham T, Hatala R. Anticoagulants for Atrial Fibrillation: Why Is the Treatment Rate So Low? *Clin Cardiol* 2002; **25**: 447-54.
48. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: The Framingham Study. *Stroke* 1991; **22**: 983-88.
49. Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. *Ann Intern Med* 1999; **131**: 492-501.
50. Beyth RJ, Antani MR, Covinsky KE, et al. Why isn't warfarin prescribed to patients with nonrheumatic atrial fibrillation? *J Gen Intern Med* 1996; **11**: 721-28.
51. Bungard T, Ghali W, Teo K, McAlister F, Tsuyuki R. Why do patients with atrial fibrillation not receive warfarin? *Arch Intern Med* 2000; **160**: 41-2.
52. Chang HJ, Bell JR, Devoo DV, Kirk JW, Wasson JH. Physician variation in anticoagulating patients with atrial fibrillation. *Arch Intern Med* 1990; **150**: 81-4.
53. Turnidge J. What can be done about resistance to antibiotics? *Brit Med J* 1998; **317**: 645-7.

54. Burke JP. Antibiotic resistance - squeezing the balloon. *JAMA* 1998; **280**: 1270-1.
55. Linder JA, Stafford RS. Antibiotic treatment of adults with sore throat by community primary care physicians: a national survey, 1989-1999. *JAMA* 2001; 1181-6.
56. Dagnelie CF, van-der-Graff Y, de Melker RA. Do patients with sore throat benefit from penicillin? A randomised double-blind placebo controlled clinical trial with penicillin V in general practice. *British Journal of General Practice* 1996; **46**(411): 589-93.
57. Middleton DB, D'Amico F, Merenstein JH. Standardized symptomatic treatment versus penicillin as initial therapy for streptococcal pharyngitis. *The Journal of Pediatrics* 1988; **113**: 1089-94.
58. Zwart S, Sachs APE, Ruijs GJHM, Gubbels JW, Hoes AW, de Melker RA. Penicillin for acute sore throat: randomised double blind trial of seven days versus three days treatment or placebo in adults. *BMJ* 2000; **320**: 150-4.
59. Linder JA, Chan JC, Bates DW. Evaluation and treatment of pharyngitis in primary care practice: The difference between guidelines is largely academic. *Arch Intern Med* 2006; **166**: 1374-9.
60. Steinman MA, Landefeld CS, Gonzales R. Predictors of broad-spectrum antibiotic prescribing for acute respiratory tract infections in adult primary care. *JAMA* 2003; **289**: 719-25.
61. Beisel L. Efficacy and safety of cefadroxil in bacterial pharyngitis. *J Int Med Res* 1980; **8** (Suppl 1): 87-93.
62. Stromberg A, Schwan A, Cars O. Five versus ten days treatment of group A streptococcal pharyngotonsillitis: a randomized controlled clinical trial with phenoxymethyl-penicillin and cefadroxil. *Scand J Infect Dis* 1988; **20**: 37-46.
63. Carbon C, Chatelin A, Bingen E, Zuck P, Rio Y. A double-blind randomized trial comparing the efficacy and safety of a 5-day course of cefotiam hexetil with that of a 10-day course of penicillin V in adult patients with pharyngitis caused by group A beta-hemolytic streptococci. *J Antimicrobial Chemother* 1995; **35**: 843-54.
64. Tack KJ, Henry DC, Gooch WM, Brink DN, Keyserling CH. Five-day cefdinir treatment for streptococcal pharyngitis. *Antimicrobial Agents Chemother* 1998; **42**: 1073-5.
65. Scaglione F. Comparison of the clinical and bacteriological efficacy of clarithromycin and erythromycin in the treatment of streptococcal pharyngitis. *Curr Med Res Opin* 1990; **12**: 25-33.

66. Bachand RT. A comparative study of clarithromycin and penicillin VK in the treatment of outpatients with streptococcal pharyngitis. *J Antimicrobial Chemother* 1991; **27(Suppl A)**: 75-82.
67. Stein GE, Christensen S, Mummaw N. Comparative study of clarithromycin and penicillin V in the treatment of streptococcal pharyngitis. *Eur J Clin Microbiol Infect Dis* 1991; **10**: 949-53.
68. Levenstein JH. Clarithromycin versus penicillin in the treatment of streptococcal pharyngitis. *J Antimicrobial Chemother* 1991; **27(Suppl A)**: 67-74.
69. Muller O, Wettich K. Clinical efficacy of dirithromycin in pharyngitis and tonsillitis. *J Antimicrobial Chemother* 1993; **31(Suppl C)**: 97-102.
70. Watkins VS, Smietana M, Conforti PM, Sides GD, Huck W. Comparison of dirithromycin and penicillin for treatment of streptococcal pharyngitis. *Antimicrobial Agent Chemother* 1997; **41**: 72-5.
71. Dykhuizen RS, Golder D, Reid TMS, Gould IM. Phenoxymethyl penicillin versus co-amoxiclav in the treatment of acute pharyngitis, and the role of beta-lactamase activity in saliva. *J Antimicrobial Chemother* 1996; **37**: 133-8.
72. Shaggner W, Ray W, Federspiel C, Miller W. Improving antibiotic prescribing in office practice: a controlled trial of three educational methods. *JAMA* 1983; **250**: 1728-32.
73. DeSantis G, Harvey K, Howard D, Mashford M, Moulds R. Improving the quality of antibiotic prescription patterns in general practice: the role of educational intervention. *Med J Austr* 1994; **160**: 502-5.
74. Brehaut JC, Stiell I., Graham I. Will a new clinical decision rule be widely used? The case of the Canadian C-Spine Rule. *Acad Emerg Med* 2006; **13**: 413-420.
75. Poses RM, De Saintonge MC, McClish DK, Smith WR, Huber HC, Alexander-Forti D *et al.* An international comparison of physicians' judgements of outcome rates of cardiac procedures and attitudes toward risk, uncertainty, justifiability and regret. *Medical Decision Making* 1998; **18**: 131-40.
76. Stone VE, Mansourati FF, Poses RM, Mayer KH. Relation of physician specialty and HIV/AIDS experience to choice of guideline recommended antiretroviral therapy. *Journal of General Internal Medicine* 2001; **16**: 360-8.
77. Dillman D. Mail and internet surveys: The tailored design. New York: John Wiley & Sons Inc., 2000.
78. Field TS, Cadoret CA, Brown ML, Ford M, Greene SM, Hill D *et al.* Surveying physicians. Do components of the "Total Design Approach" to optimizing survey response rates apply to physicians? *Medical Care* 2002; **40**: 596-606.

79. Graham I, Beardall S, Carter A, Tetroe J, Davies M. The state of the science and art of practice guideline development, dissemination, and evaluation in Canada. *Journal of Evaluation in Clinical Practice* 2003; **9**: 195-202.
80. Graham ID, Stiell IG, Laupacis A, O'Connor AM, Wells GA. Emergency physicians' attitudes toward and use of clinical decision rules for radiography. *Academic Emergency Medicine* 1998; **5**: 134-40.
81. Gilliss C, Kulkin I. Monitoring nursing interventions and data collection in a randomized clinical trial. *Western Journal of Nursing Research* 1991; **13**: 416-22.
82. Rabaneck L, Viscole C, Horwitz R. Problems in the conduct and analysis of randomized clinical trials. *Archives of Internal Medicine* 1992; **152**: 517-2.
83. Gatsonis C. Hierarchical Models in Health Services Research. In Armitage P, Colton T, eds. *Encyclopedia of Biostatistics*, New York: Wiley, 1998.
84. Goldstein H. *Multilevel Statistical Models*. London: Edward Arnold, 1995.
85. Goldstein H, Rasbash J, Plewis I, Draper D. *A User's Guide to MLWiN*. London: Institute of Education, 1998.
86. Spiegelhalter D. *BUGS 0.5: Bayesian Inference Using Gibbs Sampling, Version II*. Cambridge: MRC Biostatistics Unit, 1996.
87. Brunswik E. *Perception and the representative design of psychological experiments*. Berkeley, CA: University of California Press, 1956.
88. Castellan Jr NJ. Comments on the "lens model" equation and the analysis of multiple-cue judgement tasks. *Psychometrika* 1973; **38**: 87-100.
89. Hammond K, Brehmer B, Steinman D. Social judgement theory. In Arkes H, Hammond K, eds. *Judgement and decision making*, pp 56-76. Cambridge: Cambridge University Press, 1986.
90. Wigton RS. Use of linear models to analyze physicians' decisions. *Medical Decision Making* 1988; **8**: 241-52.
91. Tape TG, Heckerling PS, Ornato JP, Wigton RS. Use of clinical judgment analysis to explain regional variations in physicians' accuracies in diagnosing pneumonia. *Medical Decision Making* 1991; **11**: 189-97.
92. Clinical Epidemiology Unit, Ottawa Health Research Institute. Design and Analysis of Non-Randomized Clinical Trials: Simulation of effect of uneven stratification on statistical power. 2004.  
[http://www.ohri.ca/programs/clinical\\_epidemiology/asa/sample\\_size\\_calculation.asp](http://www.ohri.ca/programs/clinical_epidemiology/asa/sample_size_calculation.asp).

93. Harrell Jr. F, Lee KL, Mark D. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. *Statistics in Medicine* 1996; **15**: 361-87.
94. Wong J, Sonnenberg F, Salem D, Pauker S. Myocardial revascularization for chronic stable angina: analysis of the role of percutaneous transluminal coronary angioplasty based on data available in 1989. *Ann Intern Med* 1990; **113**: 852-71.
95. Brett A. The mammography and prostate specific antigen controversies: implications for patient-physician encounters and public policy. *J Gen Intern Med* 1995; **10**: 266-70.
96. Voss J. Prostate cancer, screening, and prostate-specific antigen: promise or peril? *J Gen Intern Med* 1994; **9**: 468-74.
97. van der Meulen J, Bouma B, van den Brink R. Comparison of therapeutic decision making in simulated paper cases and actual patients with aortic stenosis. *Med Decis Making* 1995; **15**: 428.
98. Peabody JW, Luck J, Glassman P, Dresselhaus TR, Lee M. Comparison of vignettes, standardized patients and chart abstraction. A prospective validation study of 3 methods for measuring quality. *Journal of the American Medical Association* 2000; **283**: 1715-22.
99. Jones T, Gerrity M, Earp J. Written case simulations: do they predict physicians' behavior. *J Clin Epidemiol* 1990; **43**: 805-15.
100. Chin M, Friedman P, Cassel C, Lang R. Difference in generalist and specialist physicians' knowledge and use of angiotensin-converting enzyme inhibitors for congestive heart failure. *J Gen Intern Med* 1997; **12**: 525-30.
101. Cooper G, Fortinsky R, Hapke R, Landefeld C. Primary care physician recommendations for colorectal cancer screening: patient and practitioner factors. *Arch Intern Med* 1997; **157**: 1946-50.
102. Keating N, Zaslavsky A, Ayanian J. Physicians' experiences and beliefs regarding informal consultation. *JAMA* 1998; **280**: 900-4.
103. Asch D, Jedrziewski K, Christakis N. Response rates to mail surveys published in medical journals. *Journal of Clinical Epidemiology* 1997; **10**: 1129-36.
104. Cummings S, Savitz L, Konrad T. Reported response rates to mailed physician questionnaires. *Health Services Research* 2001; **35**: 1347-55.
105. Sibbald B, Addington-Hall J, Brenneman D, Freeling P. Telephone versus postal surveys of general practitioners: methodological considerations. *British Journal of General Practice* 1994; **44**: 297-300.

106. Ubel PA. Is information always a good thing? Helping patients make "good" decisions. *Medical Care* 2002; **40**: V39-44.